Holen Sie sich die Stockscreener-App
8.33
1.19%
-0.10
Handel nachbörslich:
8.31
-0.02
-0.24%
Schlusskurs vom Vortag:
$8.43
Offen:
$8.41
24-Stunden-Volumen:
139.01K
Relative Volume:
0.31
Marktkapitalisierung:
$146.22M
Einnahmen:
$1.54M
Nettoeinkommen (Verlust:
$-38.70M
KGV:
-1.7837
EPS:
-4.67
Netto-Cashflow:
$-36.86M
1W Leistung:
+2.59%
1M Leistung:
-29.88%
6M Leistung:
+3.87%
1J Leistung:
-36.61%
1-Tages-Spanne:
$8.23
$8.54
1-Wochen-Bereich:
$8.03
$8.54
52-Wochen-Spanne:
$4.64
$20.56
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Company Profile
Firmenname
Corbus Pharmaceuticals Holdings Inc
Sektor
Branche
Telefon
617-963-0103
Adresse
500 RIVER RIDGE DRIVE, NORWOOD, MA
Vergleichen Sie CRBP mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRBP
Corbus Pharmaceuticals Holdings Inc
|
8.33 | 147.97M | 1.54M | -38.70M | -36.86M | -4.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.90 | 117.47B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
784.97 | 82.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.59 | 52.94B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
844.92 | 52.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.88 | 37.84B | 447.02M | -1.18B | -906.14M | -6.1812 |
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-30 | Fortgesetzt | B. Riley Securities | Buy |
| 2025-02-28 | Eingeleitet | William Blair | Outperform |
| 2024-12-02 | Eingeleitet | Piper Sandler | Overweight |
| 2024-07-30 | Eingeleitet | Wedbush | Outperform |
| 2024-07-22 | Fortgesetzt | H.C. Wainwright | Buy |
| 2024-06-26 | Eingeleitet | B. Riley Securities | Buy |
| 2024-06-03 | Bestätigt | Oppenheimer | Outperform |
| 2024-05-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-03-06 | Hochstufung | Jefferies | Hold → Buy |
| 2020-09-08 | Herabstufung | BTIG Research | Buy → Neutral |
| 2020-09-08 | Herabstufung | Jefferies | Buy → Hold |
| 2020-09-08 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-09-08 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2020-07-07 | Eingeleitet | ROTH Capital | Buy |
| 2020-06-17 | Eingeleitet | BTIG Research | Buy |
| 2020-03-26 | Eingeleitet | Nomura | Buy |
| 2019-04-05 | Eingeleitet | Jefferies | Buy |
| 2019-03-20 | Eingeleitet | Oppenheimer | Outperform |
| 2019-01-11 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2018-12-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-12-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2018-10-24 | Eingeleitet | B. Riley FBR | Buy |
| 2018-01-19 | Eingeleitet | Raymond James | Outperform |
| 2017-12-14 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2017-11-08 | Bestätigt | Noble Financial | Buy |
| 2017-09-29 | Fortgesetzt | Noble Financial | Buy |
| 2017-03-30 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2016-11-15 | Bestätigt | JMP Securities | Mkt Outperform |
| 2016-11-11 | Bestätigt | Noble Financial | Buy |
Alle ansehen
Corbus Pharmaceuticals Holdings Inc Aktie (CRBP) Neueste Nachrichten
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
How Corbus Pharmaceuticals Holdings Inc. (CRBP) Affects Rotational Strategy Timing - Stock Traders Daily
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors despite losses on the day - MarketWatch
Corbus Pharmaceuticals shares rise on encouraging safety results for experimental obesity drug - MSN
Downgrade Watch: Will Corbus Pharmaceuticals Holdings Inc 3371 stock top growth indexesMarket Growth Summary & Daily Volume Surge Trade Alerts - moha.gov.vn
Corbus Pharmaceuticals (NASDAQ:CRBP) Shares Cross Below Fifty Day Moving AverageShould You Sell? - MarketBeat
Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors despite daily gains - MarketWatch
Corbus Pharmaceuticals announces retirement of board member Holmer - MSN
Why Corbus Pharmaceuticals Holdings Inc. stock could outperform in 2025July 2025 Opening Moves & Weekly Chart Analysis and Guides - DonanımHaber
Can Corbus Pharmaceuticals Holdings Inc. stock sustain institutional interest2025 EndofYear Setup & Fast Exit and Entry Trade Guides - DonanımHaber
Will Corbus Pharmaceuticals Holdings Inc. stock outperform growth indexesQuarterly Trade Review & Growth-Oriented Investment Plans - DonanımHaber
Will Corbus Pharmaceuticals Holdings Inc. stock outperform value stocksJuly 2025 Drop Watch & Consistent Return Strategy Ideas - DonanımHaber
Can Corbus Pharmaceuticals Holdings Inc. stock continue upward trendJuly 2025 PreEarnings & Free Reliable Trade Execution Plans - DonanımHaber
How resilient is Corbus Pharmaceuticals Holdings Inc. stock in market downturnsJuly 2025 Sector Moves & AI Based Trade Execution Alerts - Улправда
Will Corbus Pharmaceuticals Holdings Inc. stock return to pre crisis levelsJuly 2025 Update & Entry and Exit Point Strategies - Улправда
Volume Report: How resilient is Corbus Pharmaceuticals Holdings Inc. stock in market downturnsPortfolio Gains Report & Growth Oriented Trade Recommendations - ulpravda.ru
Cormorant Asset Management, LP Reduces Stake in Corbus Pharmaceu - GuruFocus
Corbus Pharmaceuticals Announces Retirement of Board Member Holmer - TipRanks
Corbus Pharmaceuticals (CRBP) director Alan Holmer resigns from board to retire - Stock Titan
Corbus Pharmaceuticals Holdings, Inc. Announces Resignation of Alan Holmer from its Board of Directors, Effective December 31, 2025 - marketscreener.com
Rally Mode: How resilient is Corbus Pharmaceuticals Holdings Inc. stock in market downturnsJuly 2025 EndofMonth & Free Expert Verified Stock Movement Alerts - Улправда
Corbus Pharmaceuticals Holdings Inc. Stock Slides 8.6%, Underperforms Peers - 富途牛牛
Corbus Pharmaceuticals Holdings Inc. Stock Underperforms Wednesday When Compared To Competitors - 富途牛牛
Corbus Pharmaceuticals Holdings Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Cormorant Asset Management, Lp Sells 30,029 Shares of Corbus Pharmaceuticals (NASDAQ:CRBP) Stock - MarketBeat
Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors - MarketWatch
Corbus Pharmaceuticals (CRBP) insider reports 30,029-share stock sale - Stock Titan
Discipline and Rules-Based Execution in CRBP Response - news.stocktradersdaily.com
Corbus Pharmaceuticals Holdings Inc. (CRBP) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
CRBP stock surged 36% pre-market – what did its obesity treatment drug study reveal? - MSN
Corbus Pharmaceuticals Holdings Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Corbus Pharmaceuticals (CRBP) Reports Phase 1 Study Results for Obesity Drug - GuruFocus
Corbus declines following early-stage results on oral obesity asset CRB-913 (CRBP:NASDAQ) - Seeking Alpha
CRBP Stock Surged 36% Pre-Market – What Did Its Obesity Treatment Drug Study Reveal? - Stocktwits
CRBP: Corbus Pharmaceuticals' Promising Phase I Study Sparks Int - GuruFocus
CRBP: CRB-913 induced rapid, significant weight loss with minimal side effects in early obesity trials - TradingView — Track All Markets
Corbus Pharmaceuticals Reports Phase 1a Obesity Drug Data Showing Weight Loss - marketscreener.com
Corbus reports positive phase 1 results for obesity drug CRB-913 - Investing.com
Corbus Pharmaceuticals Advances Obesity Treatment with CRB-913 - TipRanks
Corbus Pharmaceuticals Reports Results From Phase 1A Study Of Oral CB1 Inverse Agonist CRB-913 For The Treatment For Obesity Demonstrating Favorable Safety Profile And Emerging Evidence Of Weight Loss - TradingView — Track All Markets
Corbus Pharmaceuticals (CRBP) Advances Obesity Treatment with CR - GuruFocus
Corbus Pharmaceuticals Announces Phase 1a Study Results of CRB-913 - TradingView — Track All Markets
Corbus Pharmaceuticals stock rises after promising obesity drug safety data By Investing.com - Investing.com UK
Corbus reports positive phase 1 results for obesity drug CRB-913 By Investing.com - Investing.com South Africa
Corbus Pharmaceuticals stock rises after promising obesity drug safety data - Investing.com
Corbus Pharmaceuticals Reports Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity Demonstrating Favorable Safety Profile and Emerging Evidence of Weight Loss - Sahm
Corbus Pharmaceuticals Holdings Inc. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
Corbus to release phase 1a study results for obesity drug CRB-913 - Investing.com
Corbus Pharmaceuticals to Report Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity on Thursday, December 11, 2025 - The Manila Times
Corbus Pharmaceuticals to Announce Phase 1a Results for CRB-913 on December 11, 2025 - Quiver Quantitative
Corbus Pharmaceuticals to Report Results from Phase 1a - GlobeNewswire
Finanzdaten der Corbus Pharmaceuticals Holdings Inc-Aktie (CRBP)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.08%
0.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):